First, we performed immunostaining for ASCL1 and NEUROD1 on SCLC tissue samples, collected from the primary tumour site, of 15 patients between 2019 and 2022 (Table S5), and observed that 14 samples were positive for ASCL1 (Fig. 1A, B). The gene discussed is NEUROD1; the disease is neoplasm.